AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

China reassured executives from American and European firms, including Apple, Qualcomm, Mastercard, Pfizer and AstraZeneca, ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Danish Prime Minister Mette Frederiksen pledged Tuesday that her government would resist what she called the unacceptable ...

Burning Rock Biotech Limited’s BNR share price has dipped by 12.36%, which has investors questioning if this is right time to ...

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

In the corporate sector, AstraZeneca (LON: AZN) stock fell 0.8% after the drugmaker agreed to buy biotechnology company ...

We recently published a list of 10 Best Stocks to Buy Now For the Long Term. In this article, we are going to take a look at ...